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A	 comprehensive,	 global	 study	 of	 sex	 disparities	 in	 contemporary	 STEMI	 care	 and	
outcomes	has	not	been	undertaken.	





Data	collected	prior	 to	2000,	 sub-categorized	data,	 and	studies	with	 less	 than	50	women	
were	 excluded.	 Meta-analyses	 were	 conducted	 using	 random	 effects	 models	 and	 are	







(32%	 female).	 Women	 were	 older	 and	 had	 more	 diabetes	 and	 hypertension.	 Overall,	
unadjusted	 in-hospital	mortality	was	2-fold	higher	 in	women	compared	to	men	(2.09	OR,	
95%CI	 1.91-2.08;	 p<0.0001),	 with	 excess	 mortality	 in	 all	 regions	 and	 time-points.		
	 iii	
Adjusting	 for	 age	 alone	 did	 not	 alter	 the	 mortality	 discrepancy.	 After	 adjustment	 for	
hypertension	and	diabetes	the	difference	in	sex-based	mortality	was	no	longer	significant.	





therapy,	 account	 primarily	 for	 the	 difference	 in	mortality.	 This	 highlights	 the	 need	 for	 a	
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Acute	 myocardial	 infarction	 (AMI)	 is	 the	 leading	 cause	 of	 death	 worldwide1-3.	
Although	 historically	 perceived	 as	 predominantly	 an	 ailment	 of	 men,	 it	 is	 the	 principal	
cause	of	death	for	women,	both	in	the	United	States	and	globally1,4.		ST-segment	Elevation	
Myocardial	 Infarction	 (STEMI),	 its	 deadliest	 form5,6,	 requires	 emergent	 reperfusion	 and	
revascularization	with	primary	percutaneous	 coronary	 intervention	 (PPCI)	 to	 reduce	 the	
high	rates	of	morbidity	and	mortality7-9.	“Time	is	myocardium”,	the	old	cardiology	maxim	
goes,	asserting	 that	successful	 intervention	 is	dependent	on	minimizing	 time	of	 ischemia.	
That	 is,	 the	 time	 from	symptom	onset	 to	 the	 restoration	of	 coronary	blood	 flow.	Current	
guidelines	 have	 set	 this	 optimal	 golden	 window,	 now	 known	 as	 door-to-balloon	 (D2B)	
time,	at	less	than	90	minutes10-12.			
Over	 the	 past	 decade,	 organizations	 such	 as	Mission	 Lifeline13-15	 (2007,	 American	
Heart	 Association)	 and	 Stent-for-Life16,17	 (2009,	 European	 Society	 of	 Cardiology)	 were	
established	to	meet	these	goals	on	a	national	and	international	level.	These	initiatives	not	
only	 tackled	 the	 root	 causes	 behind	 system-barriers	 to	 timely	 reperfusion,	 but	 also	
revolutionized	 the	 approach	 to	 STEMI	 care	 in	 the	 U.S.	 and	 Europe.	 This	 involved	
implementing	 essential	 core	 measures,	 generating	 robust	 national	 data	 registries,	
instituting	standardized	protocols	to	decrease	reperfusion	times,	and	establishing	efficient	
and	reliable	networks	of	care10,11,18-20.		
These	 US	 and	 EU	 based	 initiatives	 have	 resulted	 in	 dramatic	 improvements	 in	
STEMI	mortality	rates21-23,	but	at	the	same	time	accentuated	the	gap	in	STEMI	mortality	in	
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other	 regions	 of	 the	 world	 –	 many	 of	 which	 face	 an	 increasing	 AMI	 burden20,24.	 It	 also	
revealed	 previously	 under-recognized	 discrepancies	 in	 treatment	 times	 associated	 with	
sex,	 age,	 race,	 and	 socioeconomic	 status25-28.	 Underprivileged	 and	 traditionally	





For	decades,	 coronary	heart	 disease	 (CHD)	has	been	 a	 leading	 cause	of	morbidity	
and	mortality	for	women	worldwide.	Moreover,	since	the	1980’s,	the	annual	mortality	rate	
of	 AMI	 in	 the	 US	 has	 been	 higher	 for	 women	 than	 for	men.	 Today,	 despite	 a	 decade	 of	
considerable	improvement	in	systems	of	care	and	reduction	in	mortality	rates	in	developed	






	Still,	 despite	 mounting	 evidence	 throughout	 the	 years,	 the	 risk	 of	 cardiovascular	
disease	(CVD)	in	general,	and	CHD	in	particular,	is	frequently	underestimated	in	women.	It	




Nutrition	 Examination	 Surveys	 that	 demonstrate	 that	 over	 the	 past	 two	 decades	 the	
prevalence	of	myocardial	infarctions	has	increased	in	premenopausal	women	of	ages	34-54	
years30-32.	
Globally,	 similar	 trends	 are	 slowly	 starting	 to	 emerge33.	 Research	 from	 various	
developing	 regions	 of	 the	 world	 shows	 higher	 comorbidity	 burden	 (mainly,	 DM	 and	
hypertension)	in	women	as	compared	to	men,	as	well	as	an	accompanying	higher	CHD	and	
STEMI	mortality	rates20,24.	This	is	seen	in	research	from	South	Asia	(e.g.,	India,	Pakistan,	Sri	




As	 already	 established,	 CVD	 and	 CHD	 are	 equal	 opportunity	 killers.	 Nevertheless,	
when	 it	 comes	 to	 cardiovascular	 research,	 particularly	 clinical	 trials,	 women	 have	
historically	 been,	 and	 continue	 to	 be,	 underrepresented40-42.	 Perhaps	 the	 most	 absurd	
example	is	that	of	the	Coronary	Drug	Project43.	This	first	large	clinical	trial,	launched	by	the	
National	Heart,	 Lung,	 and	Blood	 Institute,	 included	a	 randomized	 controlled	 trial	 that,	 in	
light	of	Framingham	data	demonstrating	a	10-year	 lag	 in	 female	cardiovascular	mortality	
relative	 to	men44,	 evaluated	 the	 effects	 of	 estrogen	 for	 the	 secondary	 prevention	 of	 CHD	
exclusively	in	men	post-myocardial	infarction.	Suffice	it	to	say	that,	although	the	study	was	
stopped	 early	 due	 to	 higher	 mortality	 in	 the	 treatment	 arm,	 the	 administration	 of	
supplemental	 estrogen	 to	 postmenopausal	 women	 continued	 for	 years,	 solely	 based	 on	




reproductive	 system.	 The	 rest	 of	 the	 woman	 was	 virtually	 ignored	 in	 considerations	 of	
women’s	health”47.		
Surely	such	grave	historical	imbalances	have	been	sufficiently	addressed,	one	might	
conclude.	 Unfortunately,	 the	 historical,	 routine	 underrepresentation	 of	 women	 in	




neglected	women’s	health	needs.	 Female	 subjects	 rarely	 represent	more	 than	20-30%	of	
subjects	in	clinical	trials	and	~40%	of	most	patient	registries41,42,51.	As	a	result,	an	accurate	
epidemiologic	 snapshot	 of	 regional	 and	 global	 data	 on	 CHD	 and	 their	 dissection	 by	
geographic	 region,	 clinicopathologic	 subtype,	 temporal	 trends,	 and	 especially	 biosocial	




Consequently,	 significant	 knowledge	 gaps	 undermine	 our	 ability	 to	 accurately	














decade,	 the	 annual	 death	 rate	 for	 both	men	 and	women	 older	 than	 65	 years	 of	 age	 has	







this	 decline	 is	 absent	 or	 in	 some	 cases	 turns	 to	 an	 increase57.	 Additionally,	 there	 exist	






women	 have	 the	 highest	 MI	 prevalence	 compared	 to	 all	 other	 ethnic	 and	 racial	 women	
groups1,60.	 Additionally,	 over	 one	 third	 of	 Indian	 American	 women	 have	 three	 or	 more	
cardiac	 risk	 factors,	 and	 their	 AMI	 rates	 are	 now	 2-fold	 higher	 than	 the	 general	 US	
population61.	At	time	of	presentation,	black	and	Hispanic	women	have	more	comorbidities	
(DM,	HTN,	physical	inactivity,	higher	lipid	levels,	and	obesity)	compared	to	white	women,	










obstructive	 atherosclerotic	 disease	 in	 an	 epicardial	 vessel,	 generally	 followed	 by	
superimposed	thrombosis.	STEMI,	its	most	dreadful	form,	is	most	often	precipitated	by	the	
disruption	of	a	previously	stable	atherosclerotic	plaque	 in	an	already	narrowed	coronary	
vessel.	 Such	 a	 disruption	 exposes	 the	 vascular	 endothelium	 with	 its	 underlying	
thrombogenic	 milieu,	 which	 in	 turn	 promotes	 platelet	 aggregation,	 activation	 of	 the	
coagulation	cascade,	and	ultimately	thrombus	formation65.	The	final	result	is	an	abrupt	and	
persistent	 occlusion	 of	 the	 affected	 vessel,	 culminating	 in	 a	 complete	 cessation	 of	 blood	
flow	to	the	associated	myocardium.	It	has	long	been	established	that	the	duration	of	vessel	
occlusion	 (ischemic	 time)	 is	 directly	 proportional	 to	 infarct	 size,	 a	 phenomenon	
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characterized	 as	 “a	 wave	 front	 of	 necrosis”	 66,	 which	 is	 in	 turn	 associated	 with	 poorer	
clinical	outcomes12,67.	
Current	 evidence	 supports	 sex-based	 differences	 in	 the	 pathophysiological	
mechanisms	 underlying	 the	 aforementioned	 events68,69.	 These	 indicate	 that	women	have	
different	 plaque	 characteristics,	 pathogenicity,	 burden,	 and	 distribution,	 as	 well	 as	 an	
increased	 incidence	 of	 the	more	 rare	 syndromes	 giving	 rise	 to	 STEMI	 such	 as	 coronary	
artery	spasm	(CAS)70	and	spontaneous	coronary	artery	dissection	(SCAD)71,72.	Of	note,	this	
pathophysiological	 variability	 is	 accentuated	 in	 young	 women,	 as	 was	 recently	







men.	 This	 time	 lag	 in	 female	 morbidity	 and	 mortality	 was	 first	 demonstrated	 in	 the	
Framingham	 Population44,	 and	was	 punctuated	 by	 the	 age	 of	menopause,	 hinting	 at	 the	
atheroprotective	 effects	 of	 endogenous	 estrogen53.	 Strengthening	 this	 hypothesis	 further	
are	evidence	from	the	Women’s	Ischemia	Syndrome	Evaluation	(WISE)	study,	showing	that	
young	women	with	 endogenous	 estrogen	 deficiency	 have	 a	 sevenfold	 increased	 risk	 for	
coronary	artery	disease71.		
Although	 the	 exact	 mechanisms	 are	 not	 completely	 elucidated,	 estrogen	 was	
demonstrated	to	 inhibit	smooth	muscle	proliferation73,	and	to	 increase	nitric	oxide	 levels	
leading	 to	vasodilation74,75.	Decline	 in	 the	 levels	of	estrogen	at	menopause	was	shown	 to	
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promote	 endothelial	 dysfunction	 and	 vascular	 lipid	 deposition,	 both	 of	which	 serve	 as	 a	
preamble	 to	 AMI76,77.	 Interestingly,	 exogenous	 estrogen	 supplementation	 in	
postmenopausal	 women	 did	 not	 exhibit	 any	 efficacy	 in	 halting	 the	 progression	 of	





Plaque	rupture/disruption	 is	 the	culprit	event	 in	76%	of	men	and	55%	of	women	
with	lethal	MI79.	It	occurs	when	the	thin	fibrous	cap	encasing	a	lipid-rich,	centrally	necrotic	
atherosclerotic	plaque	is	disrupted.	This	newly	exposed	plaque	is	subsequently	infiltrated	
by	 macrophages,	 matrix	 metalloproteases,	 and	 lymphocytes,	 whose	 digestive	 actions	
expose	an	otherwise	concealed	tissue	factor	to	the	blood	stream80.	This	interaction	leads	to	
the	 activation	 of	 the	 coagulation	 cascade,	 and	 quickly	 culminates	 in	 the	 formation	 of	 an	
obstructive	thrombus.		
Evidence	suggests	that	although	plaque	rupture	is	responsible	for	the	lion	share	of	
MIs	 in	men,	plaque	erosion	 is	quite	common	 in	women,	particularly	of	young	age68,	with	
some	studies	suggesting	it	accounts	for	27%	of	patients	with	STEMI	and	31%	of	NSTEMI81.	
In	fact,	the	only	two	risk	factors	predicting	the	type	of	coronary	vessel	occlusion	are	female	
sex	 and	 premenopausal	 status.	 This	 is	 of	 particular	 interest	 since	MI	with	 non-occlusive	
CAD	is	also	more	prevalent	in	young	women82,83.	
Erosions	are	characterized	by	denuded	endothelium	covering	a	plaque	composed	of	
copious	 proteoglycans	 and	 larger	 proportions	 of	 proliferating	 smooth	 muscle	 cells	 than	
inflammatory	 cells.	 Studies	 suggest	 that	 activated	macrophages	 close	 to	 the	 endothelium	
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are	 responsible	 for	 endothelial	 apoptosis	 and	disruption	by	proteases65.	 Coronary	 vessel	
obstruction	and	AMI	develop	when	thrombi	form	on	the	surface	of	plaque	erosions,	where	
the	 dysfunctional	 endothelium	 is	 unable	 to	 keep	 the	 coagulation	 cascade	 in	 check.	
Microthrombi	can	 then	embolize,	a	phenomenon	more	commonly	associated	with	plaque	
erosion	 than	 with	 plaque	 rupture,	 causing	 downstream	 vessel	 occlusion	 and	 tissue	
infarction84,85.		
The	clinical	significance	of	 the	differences	between	rupture	and	erosion	has	yet	 to	
be	 fully	 explored.	 The	 gold	 standard	 imaging	 modality	 that	 allows	 for	 plaque	
characterization	is	optical	coherence	tomography	(OCT),	which	is	rarely	performed	due	to	
limited	availability	and	unknown	clinical	utility.	Still,	 some	studies	suggest	 the	possibility	
that	optimal	 treatment	may	differ	based	on	plaque	 type.	Namely,	 replacing	 the	 stent,	 the	
successful	workhorse	 in	 treatment	of	plaque	 rupture,	with	aspiration	 thrombectomy	and	
transcatheter	 thrombolysis	 for	 plaque	 erosion.	 Thus	 far,	 minimal	 data	 supports	 this	




Although	considered	a	 rare	mechanism	of	MI,	CAS	 is	known	 to	be	associated	with	
stable	 angina	 and	 transient	 ST–segment	 elevations	on	ECG70,89.	 Common	 triggers	 include	









EKG	 findings	 often	 mimic	 STEMI.	 Similar	 to	 other	 less	 common	 etiologies	 of	 MI,	 its	
incidence	 is	higher	 in	women,	and	clinical	suspicion	should	be	particularly	high	 in	young	
females	presenting	with	ACS	in	the	absence	of	typical	risk	factors98.	Although	the	accurate	
prevalence	of	SCAD	is	unknown,	reports	suggest	that	it	is	identified	in	10.8%	of	women	<50	
years	 of	 age	 who	 present	 with	 ACS97.	 It	 is	 also	 associated	 with	 oral	 contraceptive	 use,	







less	 severe	 pain	 and	 more	 symptoms100.	 Namely,	 they	 present	 with	 atypical	 chest	 pain	






subtle	 symptoms	 that	would	wax	 and	wane	 over	months	 prior	 to	MI112.	 Yet,	 the	 fear	 of	






For	women	 to	act	on	atypical	CHD	and	MI	symptoms	 they	must	be	aware	of	 their	
significance,	quality,	and	urgency.	Tragically,	a	national	survey	of	1000	women	conducted	
in	 2000,	 meant	 to	 assess	 knowledge,	 awareness,	 and	 perception	 of	 heart	 disease,	
discovered	a	profound	lack	of	awareness	of	gender-specific	MI	warning	signals116.	Whereas	
67%	of	 the	women	 could	 recognize	 “classic”	 signals	of	MI	 (e.g.,	 chest	pain	 and	 tightness,	
arm	 pain),	 only	 10%	 had	 knowledge	 of	 the	 symptoms	 common	 in	 women	 (e.g.,	 nausea,	
indigestion,	 fatigue).	Worse,	7%	of	 the	women	could	not	provide	any	answer.	The	survey	
also	uncovered	an	even	more	worrisome	statistic:	only	18%	of	women	 learned	about	MI	







The	seemingly	 favorable	pathologic	profile	 in	women	of	 all	 ages—less	obstructive	
CAD	 (particularly	 triple	 vessel	 and	 left	main	 disease)—results	 in	 a	 decreased	 diagnostic	
accuracy,	 namely	 an	 increased	 false-positive	 rate	with	most	 diagnostic	 tests.	 In	 addition,	





the	 treatment	 of	 diagnosed	 AMI,	 particularly	 STEMI,	 in	 developed	 countries	 has	 finally	
become	 standardized,	 and	 essentially	 gender	 neutral119-121.	 As	 previously	 discussed,	 in	
women	the	proper	implementation	of	such	therapeutic	interventions	relies	heavily	on	the	
accuracy	of	noninvasive	tests.	When	such	tests	are	abnormal,	women	are	now	more	likely	
to	 be	 referred	 to	 PCI	 than	 ever	 before119,122.	 Yet,	 the	 underrepresentation	 of	 women	 in	
studies	 of	 noninvasive	 testing	 prevents	 an	 optimal	 evidence-based	 approach	 to	 clinical	




Current	 evidence	 suggests	 that	 the	most	 cost-effective	 diagnostic	 approach	 to	 the	
evaluation	of	chest	pain	in	women	is	sequential	testing119,125.	For	both	practical	and	clinical	
reasons	 electrocardiogram	 (ECG)	 is	 often	 the	 first	 step.	 In	 the	 National	 Hospital	
Ambulatory	 Medical	 Care	 Survey,	 conducted	 by	 the	 CDC,	 younger	 women	 (<55	 years)	









The	use	of	 cardiac	 troponin	 assays	has	become	a	part	 and	parcel	 of	 the	universal	
definition	of	AMI,	with	an	increase	above	the	upper	reference	limit	being	diagnostic	of	MI	in	
patients	with	signs	and	symptoms	of	myocardial	 ischemia127.	The	universal	definition	set	
the	 upper	 reference	 limit	 as	 the	 99th	 percentile	 of	 a	 normal	 reference	 population,	
consisting	mostly	of	male	subjects.	In	recent	years,	both	the	accuracy	of	common	troponin	
assays	and	the	reference	limit	were	shown	to	be	suboptimal128.		
Recently,	 new	 high-sensitivity	 troponin	 assays	 have	 shown	 promise	 not	 only	 in	
improving	 the	diagnosis	 of	myocardial	 infarction129	 and	 leading	 to	 reductions	 in	post-MI	




effect	 in	 men	 (23%	 to	 24%	 and	 19%	 to	 21%)130,133.	 These	 data	may	 prove	 particularly	
important	not	only	 for	 the	traditional	exclusion	of	NSTEMI,	but	also	 for	young	women	or	







Exercise	 ECG	 is	 less	 sensitive	 in	 women	 due	 to	 the	 lower	 prevalence	 of	
atherosclerotic	obstruction.	Moreover,	many	women	do	not	have	 the	exercise	capacity	 to	
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attain	 the	 necessary	 intensity	 that	 maximizes	 diagnostic	 value.	 Consequently,	 the	
sensitivity	 and	 specificity	 of	 exercise	 ECG	 in	 women	 are	 61%	 and	 70%	 respectively,	 as	
compared	to	68%	and	77%	in	men134.	Furthermore,	the	rate	of	 false	positive	ST-segment	
changes	 in	women	 has	 been	 quoted	 anywhere	 from	5-	 to	 20-fold	 higher	 compared	with	
men.	 To	 improve	 the	 accuracy	 of	 exercise	 testing	 in	 women,	 the	 ACC	 Task	 Force	 on	
Exercise	Testing	recommends	myocardial	perfusion	imaging	or	stress	echocardiography	as	
better	 initial	 choices135.	 The	 accuracy	 of	 exercise	 myocardial	 perfusion	 imaging	 for	 the	
diagnosis	of	CHD	does	not	differ	between	women	and	men,	with	a	sensitivity	and	specificity	
>80%	 and	 >70%,	 respectively134.	 Exercise	 echocardiography	 was	 shown	 to	 outperform	
both	exercise	ECG	and	exercise	radionuclide	scans	in	identifying	CHD	in	women135,	with	the	









efficiency	 that	 hinges	 on	 several	 key	 principles:	 patient	 education	 (e.g.,	 quick	 symptom	
recognition	and	early	contact	with	emergency	medical	services	[EMS]);	synchronization	of	
destination	 and	 treatment	 protocols	 for	 EMS	 personnel	 (e.g.,	 merging	 the	 fastest	 route	
philosophy	 with	 choosing	 the	 most	 capable	 hospital);	 effective	 protocols	 in	 emergency	
departments	to	minimize	door-to-reperfusion	times	(e.g.,	rapid	assessment	and	activation	
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of	 the	cath	 lab);	and	finally	prompt	deployment	of	 the	most	suitable	reperfusion	strategy	
(e.g.,	 D2B	 <	 90min	 or	 thrombolysis	 <	 30min)	 by	 a	 capable	 team9,10,14,138.	 These	 are	 also	
collectively	known	as	the	STEMI	chain	of	survival.		
The	 next	 breakthrough	 in	 STEMI	 care,	 both	 in	 developed	 countries	 and	 most	
certainly	 in	 lower-income	 countries,	will	most	 likely	 result	 from	 further	 implementation	
and	 optimization	 of	 the	 assembly	 line	 to	 shorten	 total	 ischemic	 time	 (i.e.,	 Time	 to	
Treatment),	and	tailoring	reperfusion	strategies	to	specific	patient	populations139-141.	As	in	
the	 realms	 of	 epidemiology,	 pathophysiology,	 and	 diagnosis,	 previously	 discussed,	 sex	
differences	 also	 exist	 in	 the	 management	 of	 STEMI.	 These	 manifest	 both	 in	 metrics	
evaluating	 the	 efficiency	 of	 the	 chain	 of	 survival,	 as	 well	 as	 in	 clinical	 response	 to	 the	
different	reperfusion	strategies.	
Time-to-Treatment		
Given	 the	 importance	 of	 time	 to	 reperfusion67,	 the	 medical	 community	 has	 set	




afflicting	 both	men	 and	women.	Many	 studies	 have	 found	 that	 the	median	 delay	 time	 in	
seeking	care	ranges	 from	2	to	5	hours143,	with	an	overall	range	of	up	to	53.7	hours144,145.	
Although	 some	data	 indicates	 that	 upon	 recognition	of	 cardiovascular	 symptoms	women	
tend	 to	 call	9-1-1	more	often	 than	men146,	multiple	 studies	have	 found	 that	women	with	
AMI	tend	to	present	to	medical	care	later	than	men143,147,148.	One	study	found	that	while	the	
median	 symptom-to-presentation	 time	 was	 15.6	 hours	 for	 men,	 it	 was	 53.7	 hours	 in	
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women149	(both	significantly	exceeding	guidelines	of	total	 ischemic	time	<120	min).	Most	
recently,	 the	VIRGO	 trial	 showed	 that	 compared	 to	 young	man,	 young	women	who	were	






medical	 attention143.	 Lastly,	 having	 a	 history	 of	 specific	 comorbidities	 (e.g.,	 DM,	
hypertension	 and	 dyslipidemia),	 living	 alone,	 confiding	 in	 a	 family	member	 instead	 of	 a	
physician,	 and	 fear	 and	 feelings	 of	 shame	 were	 all	 associated	 with	 delays	 in	 pursuing	
treatment	options	after	the	onset	of	symptom143.		
Although	 data	 from	 various	 regions	 of	 the	 world,	 particularly	 lower-income	
countries,	 is	often	 lacking,	 it	stands	to	reason	that	 in	addition	to	region	specific	obstacles	




Thrombolytic	 agents,	most	 commonly	 tissue	 plasminogen	 activator	 (t-PA)	 and	 its	
synthetic	variants,	work	by	dissolving	occlusive	thrombi,	thus	recanalizing	culprit	vessels,	
restoring	 coronary	 blood	 flow,	 and	 minimizing	 infarct	 size65.	 In	 STEMI	 patients,	 timely	
intravenous	 fibrinolysis	 (door-to-needle	 <30	 minutes)	 improves	 survival	 over	 both	 the	
short	 and	 long	 term10,151,152,	 an	 effect	 that	 is	 independent	 of	 sex153.	 The	 most	 dramatic	
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mortality	 benefits	 are	 seen	 when	 fibrinolysis	 is	 initiated	 	 <120	 minutes	 after	 symptom	
onset154.	Consequently,	 the	ACC/AHA	STEMI	guidelines	recommend	thrombolytic	therapy	




heart	 failure,	 stroke,	 and	bleeding156-158.	The	elevated	risk	of	 reinfarction	was	 reduced	 in	




men	 and	 women,	 the	 thrombolysis-associated	 bleeding	 risk	 was	 1.43-fold	 higher	 in	
women160.	
Reported	mortality	benefits	of	thrombolysis	vary	considerably,	based	on	the	patient	
population	 and	 the	 use	 of	 adjunctive	 therapies.	 For	 example,	 in	 women,	 who	 tend	 to	
present	with	STEMI	at	significantly	older	ages,	the	effect	of	age	on	successful	thrombolysis	
is	 amplified.	 Data	 shows	 that	 older	 patients	 with	 STEMI	 have	 the	 following	 barriers	 to	





fibrinolysis	 in	 the	 majority	 of	 developed	 nations.	 Nevertheless,	 in	 many	 regions	 of	 the	
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developing	world,	where	barriers	such	as	infrastructure,	funding,	and	training	prevent	the	
establishment	 of	 an	 efficient	 PCI-capable	 system,	 thrombolysis	 continue	 to	 be	 mainstay	
therapy.	 In	 these	 regions,	 understanding	 the	 interplay	 between	 thrombolysis	 and	 sex	
remains	relevant.			
Primary	Percutaneous	Coronary	Intervention	
Today,	 PCI	 is	 an	 umbrella	 term	 for	 a	 wide	 array	 of	 procedures:	 balloons,	 stents,	
adjunct	devices,	thrombectomy,	and	pharmacologic	agent	delivery,	all	necessary	for	a	safe	
and	effective	navigation	of	a	complex	coronary	geography65.	When	performed	rapidly	and	




States	 and	most	 of	 the	 developed	world10.	 ACC/AHA	 and	 ESC	 guidelines	 for	 STEMI	 care	
define	timely	reperfusion	with	PCI	as	hospital	D2B	time	<90	minutes	for	patients	who	self-
transport	and	EMS-to-balloon	 time	<90	minutes	 for	patients	arriving	by	ambulance.	 Still,	
controversy	exists	as	to	whether	PCI	remains	the	superior	modality	in	cases	of	substantial	
delay;	as	in	places	where	24-hour	primary	PCI	is	unavailable10.	
In	 women,	 primary	 PCI	 was	 found	 to	 have	 a	 significant	 mortality	 benefit	 as	
compared	 to	 thrombolysis,	which,	 as	 previously	 discussed,	 has	 a	 very	 high	 complication	
rate.	In	the	GUSTO	II-B	trial	primary	PCI	prevented	56	deaths	per	1000	treated	patients	in	
women	 as	 compared	 to	 42	 deaths	 in	 men164.	 Despite	 almost	 eliminating	 the	 risk	 of	
intracranial	bleeding	associated	with	thrombolytic	therapy165,	women	undergoing	PCI	still	





recent	patient-level	pooled	 analysis	 of	 randomized	 trials	 in	women	undergoing	 coronary	
stenting	found	that	compared	to	bare	metal	stents	and	early	generation	drug	eluting	stents	
(DES),	 women	 receiving	 new-generation	 DES	 had	 lower	 rates	 of	 death,	 MI,	 and	 target	
vessel	revascularization169.	
Finally,	 in	 an	 analysis	 of	 22	 trials	 randomizing	 6,763	 STEMI	 patients	 to	 either	
primary	PCI	or	thrombolysis,	women	had	a	lower	30-day	mortality	with	PCI,	irrespective	of	
time	 to	 reperfusion170.	 Mortality	 rates	 were	 7.7%	 versus	 9.6%	 for	 women	 presenting	
within	the	first	2	hours	of	symptom	onset,	and	8.5%	versus	14.4%	when	presenting	after	a	
delay	 >2	 hours.	 Notably,	 the	 highest	 mortality	 was	 observed	 in	 women	 with	 a	 delayed	
presentation	who	were	treated	with	thrombolytic	therapy.	 	
Coronary	Artery	Bypass	Graft	
Emergency	 CABG	 as	 a	 treatment	modality	 for	STEMI	 is	 exceedingly	 rare.	 Even	 in	
patients	with	 triple-vessel	disease,	 it	usually	 reserved	 to	 the	post	PCI	period,	after	 initial	
vessel	patency	had	already	been	achieved.	Several	outcomes	studies,	with	data	stratified	by	
sex,	show,	that	post	CABG,	women	tend	to	have	higher	in-hospital	mortality	rates.	Although	
women	 presenting	 for	 CABG	 were	 on	 average	 older	 and	 sicker,	 adjustments	 for	 such	
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year	 mortality	 risk	 in	 both	 men	 and	 women,	 but	 the	 prediction	 strength	 and	 accuracy	
varied	between	the	sexes.	For	example,	lack	of	sinus	rhythm	was	associated	with	a	2–fold	
increased	 hazard	 ratio	 in	 women	 than	 in	 men.	 The	 study	 concluded	 that	 sex-specific	
models	 provided	 more	 accurate	 risk	 stratification	 than	 their	 traditional,	 sex-neutral	
counterparts175.		
Creating	sex-specific	models	requires	 taking	 into	account	 the	previously	described	
variations	 in	 presentation	 and	 baseline	 characteristics,	 traditional	 coronary	 risk	 factors,	
and	psychosocial	effects.	For	example,	women	with	STEMI	that	present	without	chest	pain	




other	 coronary	 risk	 factors	 such	 as	 hypertension,	 smoking,	 and	 obesity	 have	 high	
prevalence	 in	women	admitted	with	AMI,	especially	 in	developing	countries.	A	study	that	





Finally,	 there	 is	 increasing	 evidence	 that	 negative	 psychosocial	 factors,	 particularly	
depression,	 are	 associated	with	poorer	ACS	outcomes177.	 In	 patients	with	 ischemic	heart	
disease	 mental	 stress-induced	 ischemia	 increases	 mortality	 and	 recurrence	 of	 cardiac	
events	by	50%178.	These	data	are	especially	relevant	when	assessing	prognosis	in	women,	
who	 bear	 a	 higher	 burden	 of	 psychosocial	 risk	 factors	 compared	 to	 men	 at	 all	 age	
groups179,180.	 Approximately	 one	 fifth	 of	 post	 MI	 patients	 suffer	 from	 depression,	 and	
depression	rates	in	women	with	MI	are	two	fold	higher	than	in	men177.	Half	of	women	with	
AMI	 younger	 than	 fifty	 and	 over	 40%	 of	 women	 50-60	 years	 old	 suffer	 from	 clinical	
depression180.	This	increases	their	risk	of	death	or	additional	MACE	by	almost	3-fold181-183.	
Furthermore,	 social	 support	 was	 found	 to	 be	 a	 positive	 prognostic	 factors	 in	 post	 MI	
women,	 and	 is	 associated	 with	 better	 psychological	 function,	 higher	 quality	 of	 life,	 and	
reduced	rates	of	depression	one-year	post	MI184.	The	significance	of	psychosocial	stress	in	
women	with	AMI	was	also	demonstrated	 in	experimental	studies	where	emotional	stress	
was	 induced	 in	women	with	prior	 ischemic	heart	disease	or	MI,	and	was	shown	to	cause	









Over the past decade, the United States and most European countries have seen, for 
the first time, a significant reduction in ACS mortality in women. These encouraging 
trends are, in part, the result of growing awareness to long-lasting sex disparities, 
increased attention to specific cardiovascular risk factors and pathophysiology in women, 
and the implementation of evidence-based guidelines and systems of care for AMI 
patients as a whole (i.e., SFL and Mission: Lifeline).  
Nevertheless, ACS in general, and STEMI in particular, remain a leading cause of 
morbidity and mortality afflicting millions of women both in the US and worldwide. 
While the reasons for the increased incidence of AMI among women are numerous and 
may be related the increased prevalence of comorbidities, age, race, ethnicity, and 
socioeconomic trends one thing seems clear—women are late to reap the full benefits of 
the STEMI revolution that has swept most of the developed world over the past two 
decades. What is more, women in developing countries and underprivileged women in 
more developed nations bear the brunt of this persistent gender gap in STEMI care and 
outcomes.  
With the constant trickle of sporadic data on sex-based disparities in STEMI care and 
outcomes, the once considered mythical gender-gap has been receiving increasing 
amounts of attention. Nevertheless, to date, a comprehensive, global analysis of gender-
based outcome has never been performed. We believe that the first step in addressing any 
such problem is evaluating the quality of existing data (e.g., amount, connectedness), 
gauging the magnitude of the problems, and taking an initial stab at unveiling regional 
	 23	
and global trends. This meta-analysis aims to provide partial answers to these questions, 
as well as to invigorate others to collaborate and tackle these same topics. Every 
conversation needs an intermittent stimulus to remain relevant; hopefully our data will 





























only	 studies	 reporting	 sex-based	 STEMI	 mortality	 outcomes	 were	 included.	 After	 the	
exclusion	 of	 505	 studies	 based	 on	 these	 initial	 search	 criteria,	 108	 studies	 remained.	 Of	
these,	17	studies	were	excluded	because	they	spanned	data	preceding	the	year	2000.	 	An	
additional	10	studies	were	excluded	because	they	were	reviews	or	meta-analyses	and	did	
not	 include	 primary	 data,	 5	 studies	were	 excluded	 because	 the	 sex-based	mortality	 data	
were	reported	as	sub-stratified	or	 fragmented	data,	and	1	study	was	excluded	due	to	 the	
small	 sample	 size	 of	 included	 women	 (below	 50).	 	 These	 selection	 criteria	 yielded	 75	










Meta-analyses	 were	 conducted	 using	 random	 effects	 models.	 Heterogeneity	 was	
assessed	 via	 Cochran’s	 Q	 statistic.	 Odds	 ratios	 and	 95%	 confidence	 intervals	 from	 the	
random	effects	models	are	displayed	grouped	by	region	and	overall.		All	available	data	was	
used	 at	 each	 reported	 time	 point,	 there	 was	 no	 imputation	 of	 missing	 data.	 Bias	 was	
assessed	via	 visual	 assessment	of	 funnel	plots	of	 the	 effect	differences	 versus	 study	 size.	






for	 in	 hospital	 and	12-month	mortality	were	 run	 adjusting	 for	 the	 normalized	mean	 age	
(mean/standard	 deviation),	 the	 percent	 of	 men	 and	 women	 with	 hypertension	 and	 the	
percent	of	men	and	women	with	diabetes,	within	each	study.	
Contributions	




analysis	 (on	 a	 smaller	 scale	 study	 as	 a	 proof	 of	 concept).	 Helen	 Parise,	 a	 statistician	







(32%)	 women	 and	 499,697	 (68%)	 men	 (Table	 4,	 and	 Figure	 References	 section).	 The	
studies	represent	29	countries,	grouped	into	6	geographic	regions:	North	America,	Europe,	




hours)	 following	 onset	 of	 symptoms	 (Table	 6).	 	 One	 U.S.	 study	 included	 only	 patients	
presenting	with	 STEMI	 in	 cardiogenic	 shock	 and	1	 study	 from	 the	Netherlands	 excluded	
patients	with	cardiogenic	shock.		One	study	included	only	patients	with	diabetes,	2	studies	
excluded	 patients	 with	 chronic	 kidney	 disease,	 1	 study	 excluded	 patients	 with	
contraindication	 to	 anticoagulation.	 Three	 studies	 included	 only	 patients	 with	 anterior	






unadjusted	 in-hospital	 mortality	 was	 2-fold	 higher	 in	 women	 compared	 to	 men	 and	
consistently	higher	in	all	regions	evaluated	(OR	2.09;	95%	CI	1.91-2.28;	p<0.0001)	(Figure	
2).	Overall	unadjusted	mortality	rates	for	women	were	at	least	70%	higher	at	all	follow-up	





at	 30	 days	 and	 1	 year.	 The	 highest	 absolute	 in-hospital	mortality	 rates	 for	women	were	
reported	in	North	America	due	to	the	inclusion	of	a	 large	study	of	cardiogenic	shock,	and	
the	 highest	 absolute	 out-of-hospital	 mortality	 at	 30-day,	 6-month,	 and	 1-year	 follow-up	
were	reported	in	Eastern	Europe.	Review	of	the	funnel	plots	indicated	minimal	publication	
bias	(Figure	6).		
	 Sub-analysis	 excluding	 studies	 in	which	all	 patients	underwent	 reperfusion	 therapy	
(32	studies,	N=189,791)	did	not	significantly	change	overall	relative	mortality	outcomes	in-
hospital	 (2.12	 OR,	 95%CI	 1.90-2.37;	 p<0.0001),	 at	 30	 days	 (1.80	 OR,	 95%CI	 1.61-2.02;	
p<0.0001),	 or	 at	 1	 year	 (1.87	 OR,	 95%CI	 1.69-2.07;	 p<0.0001).	 Sub-analysis	 excluding	
studies	that	included	only	patients	presenting	within	a	pre-specified	time-frame	following	
onset	of	symptoms	also	did	not	significantly	change	overall	relative	mortality	outcomes	in-
hospital	 (2.09	 OR,	 95%CI	 1.90-2.30;	 p<0.0001),	 at	 30	 days	 (1.78	 OR,	 95%,	 CI	 1.56-2.03;	
p<0.0001),	or	at	1	year	(1.80	OR,	95%CI	1.63-1.98;	p<0.0001).	
	 Adjusting	 for	 age	 alone	 (N=233,039)	 in	 the	 meta-regression	 did	 not	 affect	 the	
observed	 differences	 in	mortality	 between	men	 and	women	 at	 any	 time	 point	 (OR	 1.92;	
p=0.0002	 for	 in-hospital	mortality,	 and	OR	1.71;	p=0.014	 for	12	month	mortality).	 	After	







As	 previously	 described,	 Primary	 PCI	 was	 reported	 in	 only	 16.3%	 of	 women,	
limiting	 our	 ability	 to	 accurately	 and	 comprehensively	 assess	 D2B	 times.	 Furthermore,	
there	 exists	 a	 rather	 large	 region-based	 variability	 in	 reporting	 practices,	 as	 well	 as	 in	
common	 types	 of	 interventions	 (i.e.,	 PPCI	 vs.	 thrombolysis).	 Nevertheless,	 D2B	 time	 for	
women,	 compared	 to	men,	was	 longer	 in	 all	 countries	with	 a	mean	delay	 of	 5.3	minutes	
(range:	 0-10;	 p<0.0001)	 (Figure	 5).	 Interestingly,	 the	 largest	 delays	 were	 observed	 in	
Australasia	 (9.94	min,	 95%CI	 -1.64-21.52),	 Europe	 (7.11	min,	 95%CI	 3.41-10.80),	 North	
America	(6.52	min,	95%CI	1.79-11.25),	and	in	the	Mixed	group	(4.0	min,	95%CI	0.50-7.50).		
The	 large	 delays	 in	 North	 America	 and	 Europe	 should	 be	 interpreted	 with	 the	
understanding	 that	 these	 regions	 collect	 and	 report	 the	 most	 robust	 data	 both	
quantitatively	 and	 qualitatively,	 thus	 allowing	 for	 a	 more	meaningful	 statistical	 analysis	
with	 significantly	 less	 heterogeneity.	 This	 discrepancy	 between	 observed	 delays	 in	 D2B	
times	 and	 clinical	 outcomes	 is	 highlighted	 when	 looking	 at	 data	 from	 the	 Middle	 East.	
There,	 we	 detect	 a	 minimal	 delay	 in	 D2B	 time	 (5	 min,	 95%	 -3.65-3.75),	 which	 is	 not	
statistically	 significant,	 but	 at	 the	 same	 time	 we	 observe	 the	 largest	 sex-disparity	 in	











A	 region-by-region	 analysis	 shows	 consistent	 excess	 in	 women’s	 mortality	
compared	 to	 men	 (Fig.	 2,	 3).	 This	 discrepancy	 did	 not	 spare	 the	 U.S.	 or	 Europe,	 where	
STEMI	systems	of	care	are	already	well	established.	Overall	delays	in	reported	D2B	times	
for	women,	while	 statistically	 significant,	were	 relatively	 small	 (Fig.	 5).	 Additionally,	 the	
largest	 D2B	 delays,	 detected	 in	 the	 most	 developed	 regions	 (e.g.,	 North	 America	 and	
Western	 Europe),	 merit	 a	 closer	 look.	 A	 careful	 observation	 reveals	 a	 rather	 consistent	
discordance	between	delays	in	D2B	times	and	mortality	rates.	Regions	like	Eastern	Europe	
and	the	Middle	East	exhibit	the	smallest	delays	in	D2B	times	(not	statistically	significant),	
while	at	 the	same	time	these	same	regions	suffer	 from	the	highest	 in-hospital	and	1-year	
mortality	 rates.	This	 trend	 is	 reversed	when	observing	 the	more	developed	 regions	 (e.g.,	
North	America),	where	much	longer	delays	in	D2B	times	are	recorded,	but	mortality	rates	
are	much	lower	(Fig	2,	3).	We	believe	that	this	is	the	result	of	a	lower	signal-to-noise	ratio	
in	 developing	 nations,	which	 results	 from	 the	 scarcity	 of	 standardized	 registries,	 lack	 of	
clinical	 trials,	 more	 homogeneous	 patient	 populations,	 heterogeneity	 of	 treatment	
strategies,	and	less	resources	to	implement	efficient	PCI	networks.		
Consequently,	 delays	 in	 D2B	 times	 are	 unlikely	 to	 be	 the	 principal	 driver	 of	 the	
mortality	difference.	In	fact,	among	Medicare	patients	suffering	AMI	(STEMI	and	NSTEMI),	
	 30	
Guideline Determined Medical Therapy (GDMT)	 explains	 only	 7%	 of	 the	 variation	 in	
outcomes.	 This	 not	 only	 highlights	 both	 the	 magnitude	 and	 multifactorial	 nature	 of	 the	
problem,	 but	 also	 implicates	 other	 underlying	 causes.	 Specifically,	 our	 data	 suggest	 that	




men187-190.	 Moreover,	 previous	 data	 suggest	 that	 the	 sex	 discrepancy	 in	 comorbidity	
burden	 is	 even	 more	 pronounced	 in	 developing,	 lower-income	 countries3,20,24.	 The	
significance	 of	 modifiable	 risk	 factors	 on	 mortality	 is	 emphasized	 when	 our	 analysis	 is	
adjusted	 for	 differences	 in	 age,	 hypertension,	 and	 diabetes	 (the	 most	 prevalent	 and	
consistently	reported	covariates).	Such	an	adjustment	eliminates	both	the	in-hospital	and	
12-month	disparity	in	mortality	(Table	2).		
Our	 findings	are	consistent	with	published	data	suggesting	 that,	at	 least	 in	 the	US,	
the	 higher	 STEMI	 mortality	 rate	 in	 women	 is	 largely	 due	 to	 comorbidities	 and	 the	





of	 the	developing	world,	where	systematic,	 standardized	data	collection	 is	 frequently	not	
practiced.	
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As	 previously	 discussed,	 women’s	 underrepresentation	 in	 cardiovascular	 clinical	
trials	 (~20%	 of	 enrolled	 patients)	 and	 in	 longitudinal	 studies	 and	 registries	 (~40%	 of	
enrolled	patients)	is	of	historic	magnitude.	To	add	insult	to	injury,	even	clinical	trials	that	
were	conducted	with	equal	representation,	often	were	not	sub-stratified	by	sex.	The	effect	
of	 this	 marginalization	 echoes	 even	 louder	 in	 the	 era	 of	 evidence-based	 medicine,	 as	 it	
limits	 the	 quantity	 and	 quality	 of	 sex-specific	 data	 available	 to	 both	 providers	 and	
patients42.	
Consequently,	 this	study,	which	only	 incorporates	data	 from	regions	and	hospitals	
with	 sufficient	 resources	 to	maintain	 registries,	 is	 representative	of	 a	 best-case	 scenario,	
and	does	not	adequately	capture	many	of	the	challenges	women	face	in	accessing	care.	This	
critical	 information	 gap	 masks	 upstream	 barriers	 to	 care,	 which	 often	 affect	 vulnerable	
populations,	 including	 women,	 more	 profoundly.	 These	 barriers	 may	 include	 lack	 of	
awareness	 and	 recognition	 of	 STEMI	 symptoms28,	 variations	 in	 threshold	 for	 seeking	
medical	 attention,	 insufficient	 management	 of	 modifiable	 risk	 factors,	 region-specific	
transportation,	and	financial,	social,	religious	and	cultural	impediments	to	care	11,20.		
This	 global	 analysis	 reveals	 the	 latitude	 and	magnitude	 of	 widely	 recognized	 sex	
disparities	 in	STEMI	care	and	outcomes.	However,	 its	most	powerful	 function	 is	exposing	
our	 global	 ignorance	 of	 the	 epidemiological,	 clinical,	 and	 social	 barriers	 to	 high-quality	
STEMI	 care	 for	 women.	 The	 major	 impediment	 to	 the	 improvement	 of	 STEMI	 care	 and	
outcomes	for	women	is	the	lack	of	comprehensive	and	accurate	data.		
Closing	 this	 information	 gap	 requires	 a	 rigorous	 reevaluation	 of	 sex-specific	
differences	and	their	clinical	implications.	This	long	overdue	task	should	consist	of	a	two-





and	 income	 levels	 etc.).	 An	 example	 of	 one	 such	 practical	 step	 would	 be	 changing	 the	
practice	 of	 excluding	 elderly	 patients	 from	 clinical	 trials,	 a	 “tradition”	 that	works	 to	 the	
detriment	of	women,	whose	CHD	develops	predominantly	at	older	ages.	2.	 Implementing	
public	 health	 initiatives	 to	 tackle	 economic,	 political,	 regulatory,	 cultural,	 environmental,	
health	 systems,	 and	 policy	 challenges	 both	 locally	 and	 globally193.	 A	 desperately	 needed	
first	step	 in	 improving	treatment	availability	and	outcomes	for	women	with	STEMI	 is	 the	
creation	of	large,	uniform,	global	registries	with	reliable	data	on	demographic	risk	factors,	
use	of	reperfusion,	and	patient	outcomes.	
As	 we	 enter	 the	 age	 of	 personalized	 medicine,	 attention	 to	 sex-specific	






change,	 when	 the	 Food	 and	 Drug	 Administration	 does	 not	mandate,	 sex-specific	 data	 in	






analysis	 come	 from	 larger	 hospitals	 with	 PPCI	 capabilities	 and	 individual	 data-storage	
systems,	resulting	in	a	reporting	bias	and	likely	representing	a	best-case	scenario.	Thus,	it	
is	 likely	 that	 our	 analysis	 under-estimates	 mortality	 rates	 and	 delays-to-reperfusion,	




regional	 under-reporting.	 	 For	 example,	 the	 highest	 in-hospital	 absolute	 mortality	 rates	
were	 in	 North	 America	 because	 the	 North	 American	mortality	 data	 incorporates	 a	 large	
study	 including	 only	 patients	 with	 cardiogenic	 shock.	 	 Additionally,	 the	 difference	 in	
absolute	 mortality	 rates	 raises	 concerns	 over	 systematic	 under-reporting	 of	 mortality	













Caption:	A	systematic	 literature	search	 in	PubMed	of	all	 studies	published	 from	2000	 to	
present	 was	 performed	 using	 the	 search	 terms	 “sex”,	 “gender”	 and	 “STEMI.”	 All	 studies	
written	 in	English	were	manually	 reviewed,	 and	only	 studies	 reporting	 sex-based	 STEMI	
























Caption:	While	clinical	heterogeneity	 is	present	 to	some	degree	 in	all	meta-analyses,	 the	
large	 scale	 of	 this	meta-analysis,	 the	 geographic	 variability,	 and	 the	 relatively	 large	 time	
span	 require	 an	 assessment	 of	 statistical	 heterogeneity.	 	 Bias	 was	 assessed	 via	 visual	
assessment	of	funnel	plots	of	the	effect	differences	versus	study	size			
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Figures	
Figure	1.	Search	criteria	and	methodology	for	selecting	included	studies.	
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Figure	2.	In-hospital	STEMI	mortality	by	region	
	
*	[34,	37,	39,	45,	47,	61,	62,	72,	73,	75];	†	[28,	41,	50,	55,	56,	59,	70];	‡	[1,	2,	4,	5,	6,	8,	11,	12,	13,	14,	16,	18,	21,	27,	30,	33,	36,	46,	52,	54,	
65,	66];	§	[20]	ll	[30,	69];	#	[19,	29,	32,	57,	58];	**	[23,	24,	26,	48,	51,	74]	(Reference	List	in	Appendix)	
	
	
	
	
	
	
	
Figure	3.	1	year	STEMI	mortality	by	region	
	
*	[10,	71];	†	[44,	50,	53,	55,	56,	59];	‡	[1,	5,	18,	27,	54];	§	[42,	67];	ll	[22,	32,	57,	58];	**	[2,	60]	(Reference	List	in	Appendix)	
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Figure	4.	30-day	STEMI	mortality	by	region	
	
*	[9,	10,	34,	35,	49,	71,	73]	†	[25,	43,	44,	50,	53,	55,	56,	59]	‡	[11,	63]	§	[31,	42]	ll	[64,	69]	#	[7,	22,	40]	**	[51]	(Reference	List	in	Appendix)	
	
	
	
	
	
	
Figure	5.	Delay	in	door	to	balloon	times	by	region	
	
*	[9,	10,	34,	38,	39,	47,	62,	71]	†	[25,	53,	55]	‡	[4,	6,	8,	11,	33,	62,	63,	65]	§	[31,	42,	67]	ll	[69]	#	[15,	19,	40,	68]	**	[2,	23,	51]	(Reference	
List	in	Appendix)	
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Figure	6.	Funnel	plots	for	study	variability	in	mortality	(a,b)	and	D2B	time	(c)	
	
	
	(a)	In-Hospital	Mortality	
	
	
	(b)	12-M	Mortality	
	
	
(c)	Door-to-Balloon	Time	
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Tables	
	
Table	1.	Demographics	of	patients	included	in	the	meta-	analysis	
					
(a) MI	=	Myocardial	Infarction;	*	Percentages	reflect	the	studies	that	report	the	specified	clinical	characteristic	
	
	
	
	
	
	
Table	2.	Odds	ratio	of	death	adjusted	to	clinical	variables	Give	N	for	each	group	
	
(a) HTN	=	Hypertension;	(b)	DM	=	Diabetes;	(c)	OR	=	Odds	Ratio;	*	Adjusted	for	age,	HTN	and	DM	simultaneously.	
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Table	3.	MOOSE	Checklist	
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Table	4.	Characteristics	of	studies	included	for	analysis
	
						 						*	See	Figure	References	section	for	citation	list	of	included	studies	
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Table	5.	Studies	by	geographic	region	
	
(a) Australasia	=	Australia	and	Asia		*	See	Figure	References	section	for	citation	list	of	included	studies	
	
	
	
	
	
	
Table	6.	Significant	Inclusion	and	Exclusion	Criteria	of	Included	Studies	
	
(b) STEMI	=	ST-elevation	Myocardial	Infarction	*	See	Figure	References	section	for	citation	list	of	all	studies	
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